Aptorum Group Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
Merger Integration Progress with DiamiR Biosciences QuarterlyTarget: 100% completion of all-stock merger and corporate domestication to Delaware
Clinical Trial Milestones (SACT-1 and ALS-4) AnnuallyTarget: Initiation of subsequent clinical phases following FDA End of Phase 1 meetings
Cash Runway and Capital Sufficiency Quarterly3.5MTarget: Secure additional funding via the $75 million mixed shelf registration to extend runway
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price remains below $1.00 for consecutive trading daysAction: Monitor Nasdaq deficiency notifications and evaluate potential reverse stock split or other corrective actions to maintain listing
- Completion of DiamiR Biosciences MergerTrigger: Closing of the transaction, expected before fiscal 2027Action: Execute the planned corporate domestication to Delaware and issue shares representing 70% of the combined company to DiamiR stockholders
Research as of 20 Jun 2026